Proteomic characterization of GSK3β knockout shows altered cell adhesion and metabolic pathway utilisation in colorectal cancer cells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
01
2021
accepted:
01
10
2021
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
30
12
2021
Statut:
epublish
Résumé
Glycogen-specific kinase (GSK3β) is an integral regulator of the Wnt signalling pathway as well as many other diverse signalling pathways and processes. Dys-regulation of GSK3β is implicated in many different pathologies, including neurodegenerative disorders as well as many different tumour types. In the context of tumour development, GSK3β has been shown to play both oncogenic and tumour suppressor roles, depending upon tissue, signalling environment or disease progression. Although multiple substrates of the GSK3β kinase have been identified, the wider protein networks within which GSK3β participates are not well known, and the consequences of these interactions not well understood. In this study, LC-MS/MS expression analysis was performed using knockout GSK3β colorectal cancer cells and isogenic controls in colorectal cancer cell lines carrying dominant stabilizing mutations of β-catenin. Consistent with the role of GSK3β, we found that β-catenin levels and canonical Wnt activity are unaffected by knockout of GSK3β and therefore used this knockout cell model to identify other processes in which GSK3β is implicated. Quantitative proteomic analysis revealed perturbation of proteins involved in cell-cell adhesion, and we characterized the phenotype and altered proteomic profiles associated with this. We also characterized the perturbation of metabolic pathways resulting from GSK3β knockout and identified defects in glycogen metabolism. In summary, using a precision colorectal cancer cell-line knockout model with constitutively activated β-catenin we identified several of the diverse pathways and processes associated with GSK3β function.
Identifiants
pubmed: 34739494
doi: 10.1371/journal.pone.0246707
pii: PONE-D-20-40086
pmc: PMC8570494
doi:
Substances chimiques
Glycogen Synthase Kinase 3 beta
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0246707Subventions
Organisme : Medical Research Council
ID : MR/S01411X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S025480/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Dev Growth Differ. 2009 Dec;51(9):735-42
pubmed: 19891643
Cancers (Basel). 2019 Dec 21;12(1):
pubmed: 31877793
J Biol Chem. 2012 Jun 1;287(23):19472-86
pubmed: 22496452
Mol Biol Cell. 2012 Mar;23(5):792-9
pubmed: 22238362
Nucleic Acids Res. 2013 Jan;41(Database issue):D377-86
pubmed: 23193289
Oncogene. 2015 Jul;34(27):3514-26
pubmed: 25195860
J Cell Biol. 2015 Mar 2;208(5):597-612
pubmed: 25733715
PLoS One. 2008;3(12):e4046
pubmed: 19107203
PLoS One. 2014 Mar 11;9(3):e91231
pubmed: 24618715
Cell Tissue Res. 2015 Jun;360(3):529-44
pubmed: 26017636
J Biol Chem. 2017 Nov 3;292(44):18240-18255
pubmed: 28916722
Eur J Biochem. 1979 Oct 15;100(2):339-47
pubmed: 41708
BMC Bioinformatics. 2009 Feb 03;10:48
pubmed: 19192299
F1000Res. 2017 Feb 20;6:
pubmed: 28299185
PLoS One. 2009;4(3):e4926
pubmed: 19293931
Circulation. 2014 Jul 29;130(5):419-30
pubmed: 24899689
PLoS Comput Biol. 2015 Aug 27;11(8):e1004321
pubmed: 26313928
Elife. 2015 Sep 22;4:e08022
pubmed: 26393419
J Invest Dermatol. 2008 Jun;128(6):1375-85
pubmed: 18079750
J Cell Sci. 2015 Mar 15;128(6):1150-65
pubmed: 25653389
Oncotarget. 2015 May 10;6(13):11561-74
pubmed: 25869100
PLoS One. 2011;6(7):e21800
pubmed: 21789182
Oncotarget. 2014 May 30;5(10):2881-911
pubmed: 24931005
Int J Cancer. 2008 Nov 15;123(10):2303-14
pubmed: 18729189
Nucleic Acids Res. 2016 Jan 4;44(D1):D515-22
pubmed: 26476456
Cancer Res. 2007 Aug 15;67(16):7756-64
pubmed: 17699780